Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Sep;25(5):495-502.
doi: 10.1097/CCO.0b013e328363dfee.

Insights into the broad cellular effects of nelfinavir and the HIV protease inhibitors supporting their role in cancer treatment and prevention

Soren Gantt  1 , Corey Casper, Richard F Ambinder
Affiliations
Review

Insights into the broad cellular effects of nelfinavir and the HIV protease inhibitors supporting their role in cancer treatment and prevention

Soren Gantt et al. Curr Opin Oncol. 2013 Sep.

Abstract

Purpose of review: The development of HIV protease inhibitors more than two decades ago heralded a new era in HIV care, changing the infection from universally fatal to chronic but controllable. With the widespread use of protease inhibitors, there was a reduction in the incidence and mortality of HIV-associated malignancies. Studies later found these drugs to have promising direct antitumor effects.

Recent findings: Protease inhibitors have a wide range of effects on several cellular pathways that are important for tumorigenesis and independent of inhibition of the HIV protease, including reducing angiogenesis and cell invasion, inhibition of the Akt pathway, induction of autophagy, and promotion of apoptosis. Among protease inhibitors, nelfinavir appears to have the most potent and broad antineoplastic activities, and also affects replication of the oncogenic herpesviruses Kaposi sarcoma-associated herpesvirus and Epstein-Barr virus. Nelfinavir is being studied for the prevention and treatment of a wide range of malignancies in persons with and without HIV infection.

Summary: Nelfinavir and other protease inhibitors are well tolerated, oral drugs that have promising antitumor properties, and may prove to play an important role in the prevention and treatment of several cancers. Additional insights into protease inhibitors' mechanisms of action may lead to the development of novel cancer chemotherapy agents.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Bernstein WB, Dennis PA. Repositioning HIV protease inhibitors as cancer therapeutics. Curr Opin HIV AIDS. 2008;3:666–675. - PMC - PubMed
    1. Chow WA, Jiang C, Guan M. Anti-HIV drugs for cancer therapeutics: back to the future? Lancet Oncol. 2009;10:61–71. - PubMed
    1. Agouron Pharmaceuticals I . Viracept package insert. 2009. Edited by.
    1. Adolescents PoAGfAa . In: Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Services DoHaH, editor. 2013.
    1. Blum L, Pellet C, Agbalika F, Blanchard G, Morel P, Calvo F, Lebbe C. Complete remission of AIDS-related Kaposi’s sarcoma associated with undetectable human herpesvirus-8 sequences during anti-HIV protease therapy [letter] Aids. 1997;11:1653–1655. - PubMed

Publication types

MeSH terms